Search

Your search keyword '"Ruiz-Algueró, Marta"' showing total 18 results
Start Over Author "Ruiz-Algueró, Marta" Search Limiters Available in Library Collection
18 results on '"Ruiz-Algueró, Marta"'

1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

Author

Aznar Muñoz, Esther, Gil Divasson, Pedro, González Muñiz, Patricia, Muñoz Aguirre, Clara, López, Juan Carlos, Ramírez-Schacke, Margarita, Gutiérrez, Isabel, Tejerina, Francisco, Aldámiz-Echevarría, Teresa, Díez, Cristina, Fanciulli, Chiara, Pérez-Latorre, Leire, Parras, Francisco, Catalán, Pilar, García-Leoni, María E., Pérez-Tamayo, Isabel, Puente, Luis, Cedeño, Jamil, Berenguer, Juan, Díaz Menéndez, Marta, de la Calle Prieto, Fernando, Arsuaga Vicente, Marta, Trigo Esteban, Elena, Lago Núñez, Mª del Mar, de Miguel Buckley, Rosa, Cadiñaños Loidi, Julen, Busca Arenzana, Carmen, Mican, Alfredo, Mora Rillo, Marta, Ramos Ramos, Juan Carlos, Loeches Yagüe, Belén, Bernardino de la Serna, José Ignacio, García Rodríguez, Julio, Arribas López, José Ramón, Such Diaz, Ana, Álvaro Alonso, Elena, Izquierdo García, Elsa, Torres Macho, Juan, Cuevas Tascon, Guillermo, Troya García, Jesús, Mestre Gómez, Beatriz, Jiménez González de Buitrago, Eva, Fernández Jiménez, Inés, Tebar Martínez, Ana Josefa, Brañas Baztán, Fátima, Valencia de la Rosa, Jorge, Pérez Butragueño, Mario, Alvarado Blasco, Marta, Ryan, Pablo, Sepúlveda Berrocal, Mª Antonia, Yera Bergua, Carmen, Toledano Sierra, Pilar, Cano Llorente, Verónica, Zafar Iqubal-Mirza, Sadaf, Muñiz, Gema, Martín Pérez, Inmaculada, Mozas Moriñigo, Helena, Alguacil, Ana, García Butenegro, María Paz, Peláez Ballesta, Ana Isabel, Morcillo Rodríguez, Elena, Goikoetxea Agirre, Josune, Blanco Vidal, María José, Nieto Arana, Javier, del Álamo Martínez de Lagos, Mikel, Pérez Hernández, Isabel A., Pérez Zapata, Inés, Silvariño Fernández, Rafael, Ugalde Espiñeira, Jon, Asensi Álvarez, Víctor, Suárez Pérez, Lucia, Suárez Diaz, Silvia, Yllera Gutiérrez, Carmen, Boix, Vicente, Díez Martínez, Marcos, Carreres Candela, Melissa, Gómez-Ayerbe, Cristina, Sánchez-Lora, Javier, Velasco Garrido, José Luis, López-Jódar, María, Santos González, Jesús, Ruiz Aragón, Jesús, Virto Peña, Ianire, Alende Castro, Vanessa, Brea Aparicio, Ruth, Vega Molpeceres, Sonia, Pons Viñas, Estel, del Río Pérez, Oscar, Valero Rovira, Silvia, Villar-García, Judit, Gómez-Junyent, Joan, Knobel, Hernando, Cánepa, María Cecilia, Castañeda Espinosa, Silvia, Sorli Redò, Luisa, Güerri-Fernández, Roberto, Milagro Montero, María, Horcajada, Juan Pablo, García Vázquez, Elisa, Moral Escudero, Encarnación, Hernández Torres, Alicia, García Almodóvar, Esther, Sáez Barberá, Carmen, Karroud, Zineb, Hernández Quero, José, Vinuesa García, David, García Fogeda, José Luis, Peregrina, José Antonio, Novella Mena, María, Hernández Gutiérrez, Cristina, Sanz Moreno, José, Pérez Tanoira, Ramón, Sierra Rodríguez, Rodrigo, Alonso Menchén, David, Gutiérrez García, Aida, Arranz Caso, Alberto, Cuadros González, Juan, Álvarez de Mon Soto, Melchor, Díaz de Brito Fernández, Vicente Ferrer, Sanmarti Vilamala, Montserrat, Gabarrell Pascuet, Aina, Molina Morant, Daniel, España Cueto, Sergio, Cámara Fernández, Jonathan, Sabater Gil, Albert, Muñoz López, Laura, Sáez Escolano, Paula, Bejarano Tello, Esperanza, Sempere Alcocer, Marco Antonio, Álvarez Martin, Salvador, De los Santos Gil, Ignacio, García-Fraile, Lucio, Sampedro Núñez, Miguel, Barrios Blandino, Ana, Rodríguez Franco, Carlos, Useros Brañas, Daniel, Villa Martí, Almudena, Oliver Ortega, Javier, Costanza Espiño Álvarez, Alexia, Sanz Sanz, Jesús, Rexach Fumaña, María, Abascal Cambras, Ivette, Pérez Jaén, Ana del Cielo, Sala Jofre, Clara, Casas Rodríguez, Susana, Tortajada Alamilla, Cecilia, Oltra, Carmina, Masiá Canuto, Mar, Gutiérrez Rodero, Félix, Ferrer Ribera, Ana, Bea Serrano, Carlos, Pedromingo Kus, Miguel, Garcinuño, María Ángeles, Fiorante, Silvana, Pérez Pinto, Sergio, Hernández Machín, Pilar, Alastrué Violeta, Alba, Fariñas Álvarez, María Carmen, González Rico, Claudia, Arnaiz de las Revillas, Francisco, Calvo, Jorge, Gozalo, Mónica, Mora Gómez, Francisco, Milagro Beamonte, Ana, Latorre-Millán, Miriam, Rezusta López, Antonio, Martínez Sapiña, Ana, Meije, Yolanda, Duarte Borges, Alejandra, Pareja Coca, Julia, Clemente Presas, Mercedes, Losa García, Juan Emilio, Vegas Serrano, Ana, Pérez-Rodríguez, M. Teresa, Pérez González, Alexandre, Belhassen-García, Moncef, Rodríguez-Alonso, Beatriz, López-Bernus, Amparo, Carbonell, Cristina, Torres Perea, Rafael, Cantón de Seoane, Juan, Alonso, Blanca, Kamal, Sara Lidia, Cajuela, Lucia, Roa, David, Cervero, Miguel, Oreja, Alberto, Avilés, Juan Pablo, Martín, Lidia, Pelegrín Senent, Iván, Rouco Esteves Marques, Rosana, Parra Ruiz, Jorge, Ramos Sesma, Violeta, Abadia Otero, Jessica, Salillas Hernando, Juan, Torres Sánchez del Arco, Robert, Torralba González de Suso, Miguel, Serrano Martínez, Alberto, Gilaberte Reyzábal, Sergio, Pacheco Martínez-Atienza, Marina, Liébana Gómez, Mónica, Fernández Rodríguez, Sara, Varela Plaza, Álvaro, Calvo Sánchez, Henar, Martínez Martín, Patricia, González- Ruano, Patricia, Malmierca Corral, Eduardo, Rábago Lorite, Isabel, Pérez-Monte Mínguez, Beatriz, García Flores, Ángeles, Comas Casanova, Pere, Sirisi, Merce, Rojas, Richard, Díaz de Tuesta del Arco, José Luis, Figueroa Cerón, Ruth, González Sarria, Ander, Alemán Valls, Remedios, Alonso Socas, María del Mar, Sanz Peláez, Oscar, Mohamed Ramírez, Karim, Riera Jaume, Melchor, Vilchez, Helem Haydee, Albertí, Francesc, Cañabate, Ana Isabel, Moreno Cuerda, Víctor J., Álvarez Kaelis, Silvia, Álvarez Zapatero, Beatriz, García García, Alejandro, Isaba Ares, Elena, Morcate Fernández, Covadonga, Pérez Rodríguez, Andrea, Ramos Merino, Lucía, Castelo Corral, Laura, Rodríguez Mahía, María, González Bardanca, Mónica, Sánchez Vidal, Efrén, Míguez Rey, Enrique, De la Torre Lima, Javier, García de Lomas Guerrero, José Mª, Morte, Elena, Loscos, Silvia, Camón, Ana, Gómez García, Lucía, Boix Palop, Lucia, Dietl Gómez-Luengo, Beatriz, Pedrola Gorrea, Iris, Blasco Claramunt, Amparo, López Mestanza, Cristina, Fraile Villarejo, Esther, Tosco Núñez, Tomás, Aroca Ferri, María, Algado Rabasa, José Tomas, Garijo Saiz, Ana María, Amador Prous, Concepción, Baño, Jesús Rodriguez, Retamar, Pilar, Valiente, Adoración, López-Cortés, Luis E., Sojo, Jesús, Gutiérrez-Gutiérrez, Belén, Bravo-Ferrer, José, Salamanca, Elena, Palacios, Zaira R., Pérez-Palacios, Patricia, Peral, Enrique, Pérez de León, José Antonio, Sánchez-Gómez, Jesús, Marín-Barrera, Lucía, García-Jiménez, Domingo, Carratalà, Jordi, Abelenda-Alonso, Gabriela, Ardanuy, Carmen, Bergas, Alba, Cuervo, Guillermo, Domínguez, María Ángeles, Fernández-Huerta, Miguel, Gudiol, Carlota, Lorenzo-Esteller, Laia, Niubó, Jordi, Pérez-Recio, Sandra, Podzamczer, Daniel, Pujol, Miquel, Rombauts, Alexander, Trullen, Núria, Salavert Lletí, Miguel, Castro Hernández, Iván, Hernández Belmonte, Adriana, Martínez Goñi, Raquel, Navarro Vilasaró, Marta, Calzado Isbert, Sonia, Cervantes García, Manuel, Gomila Grange, Aina, Gasch Blasi, Oriol, Machado Sicilia, María Luisa, Van den Eynde Otero, Eva, Falgueras López, Luis, Navarro Sáez, María del Carmen, Martínez, Esteban, Marcos, Mª Ángeles, Mosquera, Mar, Blanco, José Luis, Laguno, Montserrat, Rojas, Jhon, González-Cordón, Ana, Inciarte, Alexy, Torres, Berta, De la Mora, Lorena, Soriano, Alex, Martínez Macias, Olalla, Pérez Doñate, Virginia, Cabello Úbeda, Alfonso, Carrasco Antón, Nerea, Álvarez Álvarez, Beatriz, Petkova Saiz, Elizabet, Górgolas Hernández-Mora, Miguel, Prieto Pérez, Laura, Carrillo Acosta, Irene, Heili Frades, Sara, Villar Álvarez, Felipe, Fernández Roblas, Ricardo, Milicua Muñoz, José María, Fernández Espinilla, Virginia, Dueñas Gutiérrez, Carlos Jesús, Hernán García, Cristina, González-Romo, Fernando, Merino Amador, Paloma, Rueda López, Alba, Martínez Jordán, Jorge, Medrano Pardo, Sara, Díaz de la Torre, Irene, Posada Franco, Yolanda, Delgado-Iribarren, Alberto, López-Contreras González, Joaquín, Pascual Alonso, Pablo, Pomar Solchaga, Virginia, Rabella García, Nuria, Benito Hernández, Natividad, Domingo Pedrol, Pere, Bonfill Cosp, Xavier, Padrós Selma, Rafael, Puig Campmany, Mireia, Mancebo Cortés, Jordi, Gurguí Ferrer, Mercè, Íñigo Pestaña, Melania, Pérez García, Alejandra, Sorní Moreno, Patricia, Izko Gartzia, Nora, Membrillo de Novales, Francisco Javier, Simón Sacristán, María, Zamora Cintas, Maribel, Martínez Martínez, Yolanda, Fernández-González, Pablo, Alcántara Nicolás, Francisco, Aguirre Vila-Cora, Alejandro, López Tizón, Elena, Ramírez-Olivencia, Germán, Estébanez Muñoz, Miriam, Sáez de Adana Arróniz, Ester, Portu Zapirain, Joseba, Gainzarain Arana, Juan Carlos, Ortiz de Zárate Ibarra, Zuriñe, Moran Rodríguez, Miguel Ángel, Canut Blasco, Andrés, Hernáez Crespo, Silvia, Balerdi Sarasola, Leire, Morales García, Cristina, Corral Saracho, Miguel, Valcarce González, Zeltia, Arenal Andrés, Noelia, Rodríguez Tarazona, Raquel Elisa, Iglesias Llorente, Laura, Loureiro Rodríguez, Beatriz, Sánchez Montalvá, Adrián, Espinosa Pereiro, Juan, Almirante, Benito, Miarons, Marta, Sellarés, Júlia, Larrosa, María, García, Sonia, Marzo, Blanca, Villamarín, Miguel, Fernández, Nuria, Pérez-Jorge Peremarch, Conchita, Resino Foz, Elena, Espigares Correa, Andrea, Álvarez de Espejo Montiel, Teresa, Navas Clemente, Iván, Quijano Contreras, María Isabel, Nieto Fernández del Campo, Luis Alberto, Jiménez Álvarez, Guillermo, Guillamón Sánchez, Mercedes, García García, Josefina, Muñoz Hornero, Constanza, Mariño Callejo, Ana, Valcarce Pardeiro, Nieves, Smithson Amat, Alex, Chico Chumillas, Cristina, Sánchez Serrano, Adriana, García Villalba, Eva Pilar, Jiménez Martínez, Isabel, Estrada Fernández, Guillermo, Lorén Vargas, María, Parra Arribas, Nuria, Martínez Cilleros, Carmen, Villasante de la Puente, Aránzazu, García Delange, Teresa, Ruiz Rodríguez, María José, Robledo del Prado, Marta, Abad Almendro, Juan Carlos, Muñoz del Rey, José Román, Jiménez Álvaro, Montaña, Coy Coy, Javier, Poquet Catala, Inmaculada, Santos Peña, Marta, Naranjo Velasco, Virginia, Manso Gómez, Tamara, Quilez Ágreda, Delia, Barbeito Castiñeiras, Gema, Domínguez Santalla, María Jesús, Mao Martín, Laura, Alonso Navarro, Rodrigo, Ampuero Martinich, Jose David, Barrós González, Raquel, Galindo Martín, María Aránzazu, Herrera Pacheco, Lourdes, Martínez Avilés, Rocío, Rodrigo González, Sara, Rodríguez Leal, Cristóbal Manuel, Romay Lema, Eva María, Suárez Gil, Roi, Ibarguren Pinilla, Maialen, Marimón Ortiz de Zárate, José María, Vidaur Tello, Loreto, Kortajarena Urkola, Xabier, García Gómez, Miriam, Aranguren Arostegui, Asier, Álvarez de Castro, Maria, Martínez Mateu, Cintia María, Rodríguez Gómez, Francisco, Muñoz Beamud, Francisco, Chamarro Martí, Elena, Cardona Rivera, Merce, Zakariya-Yousef Breval, Ismail, Rico Rodríguez, Marta, Llenas García, Jara, Sánchez Arenas, Mª Carmen, Fernández Cruz, Ana, Calderón Parra, Jorge, López Dosil, Marcos, Ramos Martínez, Antonio, Múñez Rubio, Elena, Callejas Díaz, Alejandro, Vázquez Comendador, José Manuel, Diego Yagüe, Itziar, Expósito Palomo, Esther, Anel Pedroche, Jorge, Álvarez Franco, Raquel, Fernández de Orueta, Lucía, Vates Gómez, Roberto, Cardona Arias, Andrés Felipe, Marguenda Contreras, Pablo, Gaspar Alonso-Vega, Gabriel, Aranda Rife, Elena María, Martínez Cifre, Blanca, Roger Zapata, Daniel, Martín Rubio, Irene, Barbosa Ventura, André, Piñero, Iván, Bahamonde Carrasco, Alberto, Runza Buznego, Paula, Talavera García, Eva, Lamata Subero, Marta, Urrutia Losada, Ainhoa, Arteche Eguizabal, Lorea, Delgado Sánchez, Elisabet, Molina Peinado, Virginia, Caro Bragado, Sarah, Domínguez de Pablos, Gema, Roldán Fontana, Carolina, Herrero Rodríguez, Carmen, Force Sanmartín, Luis, Aranega, Raquel, Mera Fidalgo, Arantzazu, Toda Savall, María Roca, Merchante Gutiérrez, Nicolas, León Jiménez, Eva María, Del Pozo, José Luís, Serralta Buades, Josefa, Cabrera Tejada, Ginger Giorgiana, Fernández-Ruiz, Mario, Aguado, José María, Maestro de la Calle, Guillermo, Cisneros, José Miguel, Pachón, Jerónimo, Aguilar-Guisado, Manuela, Aldabó, Teresa, Avilés, María Dolores, Bueno, Claudio, Cordero-Matía, Elisa, Escoresca, Ana, Gálvez-Benítez, Lydia, Infante, Carmen, Martín, Guillermo, Praena, Julia, Roca, Cristina, Salamanca, Celia, Suárez-Benjumea, Alejandro, Vizcarra, Pilar, Quereda, Carmen, Rodriguez Dominguez, Mario José, Gioia, Francesca, Norman, Francesca, Del Campo, Santos, Cantón Moreno, Rafael, Oteo Revuelta José, Antonio, Santibáñez Sáenz, Paula, Cervera Acedo, Cristina, Ruiz Martínez, Carlos, Blanco Ramos, José R., Azcona Gutiérrez, José M., García García, Concepción, Alba Fernández, Jorge, Ibarra Cucalón, Valvanera, San Franco, Mercedes, Metola Sacristán, Luis, Meijide Míguez, Héctor, Paulos Viñas, Silvia, Menéndez, Justo, Villares Fernández, Paula, Montes Andújar, Lara, Navarro Batet, Álvaro, Ferrer Santolaria, Anna, Padilla Salazar, María de la Luz, Abella Vázquez, Lucy, Hayek Peraza, Marcelino, García Pardo, Antonio, Hernández Carballo, Carolina, Ruiz Fernández, Andrés Javier, Barrio López, Isabel, Martakoush, Alí, Rojas-Vieyra, Agustín, García Calvo, Sonia, Villarreal García-Lomas, Mercedes, Vizcaíno Callejón, Marta, García García, María Pilar, Lérida Urteaga, Ana, Carrasco Fons, Natalia, María Sanjuan, Beatriz, Martín González, Lydia, Sanz Zamudio, Camilo, Jarrín, Inmaculada, Alejos, Belén, Moreno, Cristina, Rava, Marta, Iniesta, Carlos, Izquierdo, Rebeca, Suárez-García, Inés, Díaz, Asunción, Ruiz-Alguero, Marta, Hernando, Victoria, Rodríguez-Baño, Jesús, Yllescas, María, and Arriba, José Ramón

Published
2020
Full Text
View/download PDF

2. Patients’ experiences and opinions after de-simplification of their single-tablet regimens for the treatment of HIV infection: a survey in a multicentre cohort

Author

Suárez-García, Inés, Ruiz-Algueró, Marta, Alejos, Belén, García-Yubero, Cristina, Belza, Ma José, Espacio, Ramón, Hernández, Juanse, Sánchez, Josefa Muñoz, Garaialde, Ainhoa, Socas, María del Mar Alonso, Alcaraz, Antonia, Ruiz de Galarreta, Beatriz Pierola, Martínez Madrid, Onofre Juan, Cuéllar, Isabel Gutiérrez, Gómez-Ayerbe, Cristina, Olalla, Julián, and Jarrín, I

Published
2022
Full Text
View/download PDF

3. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single?tablet regimen in a multicentre cohort in Spain

Author

Suárez?García, Inés, Alejos, Belén, Ruiz?Algueró, Marta, Yubero, Cristina García, Moreno, Cristina, Bernal, Enrique, Pérez?Is, Laura, Zubero, Zuriñe, Fernández, Miguel Alberto Zárraga, Abad, Gloria Samperiz, and Jarrín, Inma

Subjects
Drug therapy, Comparative analysis, Patient outcomes, Dosage and administration, Lamivudine -- Dosage and administration -- Comparative analysis, HIV infections -- Drug therapy -- Patient outcomes, Abacavir -- Dosage and administration -- Comparative analysis, Generic drugs -- Dosage and administration -- Comparative analysis, Dolutegravir -- Dosage and administration -- Comparative analysis, Combination drug therapy -- Comparative analysis, Drug therapy, Combination -- Comparative analysis, HIV infection -- Drug therapy -- Patient outcomes
Abstract

INTRODUCTION Highly active antiretroviral therapy (ART) has substantially increased the life expectancy of people living with HIV [1,2]. People living with HIV (PLHIV) have a life expectancy that can reach [...], : Introduction: We aimed to assess the effectiveness and tolerability of dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) administered as branded STR (DTG/ABC/3TC) or as two separate pills (DTG and either branded ABC/3TC [DTG+(ABC/3TC)b] or generic ABC/3TC [DTG+(ABC/3TC)g]). Methods: We included individuals from the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) who received DTG/ABC/3TC, DTG+(ABC/3TC)b or DTG+(ABC/3TC)g during 2015 to 2018. We used multivariable logistic regression to compare the proportion of antiretroviral?naïve individuals who achieved viral suppression (VS) (viral load ?50 copies/mL) at 24 weeks of initiating with DTG+(ABC/3TC)b or DTG+(ABC/3TC)g versus DTG/ABC/3TC. We also calculated the proportion of virologically suppressed individuals who maintained VS at 24 weeks after switching from DTG/ABC/3TC to DTG+(ABC/3TC)g. Results: During the study period, 829, 68 and 47 treatment?naïve individuals started treatment with DTG/ABC/3TC, DTG+(ABC/3TC)b or DTG+(ABC/3TC)g respectively. The proportions of individuals who changed their regimens due to side effects during the first 24 weeks were 3.7%, 4.4% and 6.4% respectively (p = 0.646). We did not find significant differences in VS at 24 weeks among individuals starting with DTG+(ABC/3TC)b or DTG+(ABC/3TC)g compared to those initiating with DTG/ABC/3TC. Among 177 virologically suppressed individuals who switched from DTG/ABC/3TC to DTG+(ABC/3TC)g, 170 (96.0%) maintained VS at 24 weeks. Conclusions: In naïve individuals, the effectiveness and tolerability at 24 weeks of DTG plus ABC/3TC administered as two separate pills, either as branded or generic ABC/3TC, was similar to the STR DTG/ABC/3TC. Switching the STR DTG/ABC/3TC to its separate components DTG+(ABC/3TC)g in virologically suppressed individuals did not seem to impair its effectiveness.

Published
2021
Full Text
View/download PDF

4. Impacto de la pandemia de la COVID-19 en los sistemas de vigilancia epidemiologica de la infección por VIH en España

Author

Godoy, Pere, Simón Méndez, Lorena, Ruiz Algueró, Marta, Díaz Franco, Asunción, Godoy, Pere, Simón Méndez, Lorena, Ruiz Algueró, Marta, and Díaz Franco, Asunción

Abstract

BACKGROUND // The COVID-19 pandemic indirectly affected other communicable diseases, such as human immunodeficiency virus (HIV) infection. The aim of this paper was to evaluate the impact of the COVID-19 pandemic on the epidemiological surveillance of HIV through epidemiological indicators. METHODS // Data collected in the New HIV Diagnosis Information System (SINIVIH, acronym in Spanish) in the period 2013-2021 was analyzed. The epidemiological indicators analyzed were: 1) Reporting delay of new diagnoses; 2) Under diagnosis of cases, calculated per month of diagnosis and for each year of diagnosis; 3) Late diagnosis, cases diagnosed with less than 350 CD4 cell/mm3. RESULTS // Regarding the reporting delay of new diagnoses, in 2022 2,770 diagnoses were reported in 2020, 43.8% more than those reported in 2021 for that year. The cases diagnosed per month between 2016 and 2019 followed a constant trend. In 2020, a significant decrease in diagnoses was observed between March and May that was not recovered after correcting for reporting delay. When comparing the rates of cases diagnosed in 2013 with the successive years, a continuous decrease was interrupted in the last year of the study period. The percentage of cases with late diagnosis had remained stable in the study period (between 46% and 50%), and a decrease in this percentage was observed after correcting for reporting delay. CONCLUSIONS // The epidemiological surveillance of HIV suffered a significant reporting delay. A decrease in cases diagnosed is confirmed, partly due to lockdown and lack of access to the health system. Changes on late diagnosis is not observed., FUNDAMENTOS // La pandemia de la COVID-19 afectó de forma indirecta a otras enfermedades transmisibles, como la infección por el virus de la inmunodeficiencia humana (VIH). El objetivo de este estudio fue evaluar el impacto de la pandemia de la COVID-19 en la vigilancia epidemiológica del VIH a través de indicadores epidemiológicos. MÉTODOS // Se analizaron los datos recogidos en el Sistema de Información de Nuevos Diagnósticos de VIH (SINIVIH) en el periodo 2013-2021. Los indicadores epidemiológicos analizados fueron: 1) Retraso en la notificación de nuevos diagnósticos; 2) Infradiagnóstico de caso, calculado por mes y por cada año de diagnóstico; 3) Diagnóstico tardío, casos diagnosticados con menos de 350 células CD4/mm3. RESULTADOS // Respecto al retraso en la notificación de nuevos diagnósticos, en 2022 se notificaron 2.770 casos diagnosticados en 2020, un 43,8% más respecto a los notificados en 2021 para ese año. Los casos diagnosticados por mes entre 2016 y 2019 seguían una tendencia constante. En 2020 se observó un descenso importante de diagnósticos entre marzo y mayo que no se recuperó al corregir por retraso en la notificación. Al comparar las tasas de casos diagnosticados en 2013 con los años sucesivos, se observó un descenso continuo que se interrumpía en el último año del periodo de estudio. El porcentaje de casos con diagnóstico tardío se mantuvo estable en el periodo de estudio (entre el 46% y el 50%), observándose un descenso al corregir por retraso en la notificación. CONCLUSIONES // La vigilancia epidemiológica del VIH sufrió un importante retraso en la notificación. Se constata un descenso en los casos diagnosticados, en parte debido al confinamiento y la falta de acceso a pruebas diagnósticas. No se observan cambios en el diagnóstico tardío.

Published
2023

6. Papel de la farmacoepidemiología en la monitorización del continuo de atención del VIH

Author

Ruiz Algueró, Marta, Díaz Franco, Asunción, Jarrín Vera, Inma, and UAM. Departamento de Medicina Preventiva y Salud Pública y Microbiología

Subjects
Medicina
Abstract

Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Medicina Preventiva y Salud Pública y Microbiología. Fecha de Lectura: 24-11-2022

Published
2022

7. Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort

Author

Suárez-García, Inés, primary, Ruiz-Algueró, Marta, additional, Alejos, Belén, additional, García-Yubero, Cristina, additional, Belza, Mª José, additional, Espacio, Ramón, additional, Hernández, Juanse, additional, Muñoz Sánchez, Josefa, additional, Garaialde, Ainhoa, additional, Alonso Socas, María del Mar, additional, Alcaraz, Antonia, additional, Pierola Ruiz de Galarreta, Beatriz, additional, Martínez Madrid, Onofre Juan, additional, Gutiérrez Cuéllar, Isabel, additional, Gómez-Ayerbe, Cristina, additional, Olalla, Julián, additional, and Jarrín, Inma, additional

Published
2022
Full Text
View/download PDF

8. Temporal trends and geographic variability in the prescription of antiretroviral treatments in people living with hiv in spain, 2004–2020

Author

Ruiz Algueró, Marta, Hernando, Victoria, Riero, María, Blanco Ramos, José Ramón, Zárraga Fernández, Miguel Alberto de, Galindo, Pepa, Pérez González, Alexandre, Díaz, Asunción, Suárez García, Inés, Jarrín, Inmaculada, CoRIS, Instituto de Salud Carlos III, Red de Investigación Cooperativa en Investigación en Sida, European Regional Development Fund, and Plan Nacional de I+D+i (España)

Subjects
Tratamiento médico, Sida, Estudios de cohortes, Cohort studies, General Medicine, antiretroviral therapy, trends, HIV infection, cohort studies, Trends, Terapia antirretroviral altamente activa, Antiretroviral therapy
Abstract

Background: The purpose of this study was to describe temporal trends in the use of antiretroviral therapy (ART) among people living with HIV (PLWHIV) from the cohort of the Spanish HIV/AIDS research network (CoRIS), 2004-2020. Methods: We described the yearly evolution of the proportion of patients receiving ART and the most frequently prescribed antiretroviral drugs among newly recruited treatment-naïve patients and among all patients with active follow-up. Results: Of 15,539 patients included, 14,618 (94.1%) started ART during their follow-up. Regarding initial regimens, the use of 2NRTI plus 1NNRTI (which were the most frequently prescribed until 2014) and 2NRTI plus 1bPI decreased after 2014, being gradually replaced by INI-based triple therapies. Since 2019, other regimens started to be prescribed, mainly dual therapies. TDF/FTC/EFV was the single-tablet regimen (STR) most frequently prescribed as initial ART until 2012, decreasing thereafter as TDF/FTC/RPV, TDF/FTC/EVG/COBI, and ABC/3TC/DTG became available. TAF/FTC/BIC accounted for 53.6% of initial prescriptions in 2020, followed by DTG/3TC (24%). The percentage of patients on ART increased from 45.7% in 2004 to 98.2% in 2020. Among all patients receiving ART, regimens based on 2NRTI plus 1INI increased from 0.1% in 2007 to 53.3% in 2020. During 2007-2015, most patients were receiving TDF/FTC/EFV, which was replaced after 2017 by ABC/3TC/DTG. In 2020, 13.0% of patients were receiving dual therapies. Conclusions: Robust real-world data on ART use in PLWHIV over more than 15 years show historical trends in prescriptions with an unprecedented visualization of the contemporary treatment patterns. Instituto de Salud Carlos III Red Temática deInvestigación Cooperativa en Sida (RD06/006, RD12/0017/0018 y RD16/0002/0006 Instituto de Salud Carlos III-Subdirección General deEvaluación y el Fondo Europeo de Desarrollo Regional (FEDER) 4.964 JCR (2021) Q2, 54/172 Medicine, General & Internal 1.040 SJR (2021) Q1, 438/2489 Medicine (miscellaneous) No data IDR 2020 UEM

Published
2022

9. Temporal Trends and Geographic Variability in the Prescription of Antiretroviral Treatments in People Living with HIV in Spain, 2004–2020.

Author

Ruiz-Algueró, Marta, Hernando, Victoria, Riero, María, Blanco Ramos, José Ramón, de Zarraga Fernández, Miguel Alberto, Galindo, Pepa, Pérez-González, Alexandre, Díaz, Asunción, Suárez-García, Inés, and Jarrín, Inma

Subjects
*HIV-positive persons, *ANTIRETROVIRAL agents, *MEDICAL prescriptions
Abstract

Background: The purpose of this study was to describe temporal trends in the use of antiretroviral therapy (ART) among people living with HIV (PLWHIV) from the cohort of the Spanish HIV/AIDS research network (CoRIS), 2004–2020. Methods: We described the yearly evolution of the proportion of patients receiving ART and the most frequently prescribed antiretroviral drugs among newly recruited treatment-naïve patients and among all patients with active follow-up. Results: Of 15,539 patients included, 14,618 (94.1%) started ART during their follow-up. Regarding initial regimens, the use of 2NRTI plus 1NNRTI (which were the most frequently prescribed until 2014) and 2NRTI plus 1bPI decreased after 2014, being gradually replaced by INI-based triple therapies. Since 2019, other regimens started to be prescribed, mainly dual therapies. TDF/FTC/EFV was the single-tablet regimen (STR) most frequently prescribed as initial ART until 2012, decreasing thereafter as TDF/FTC/RPV, TDF/FTC/EVG/COBI, and ABC/3TC/DTG became available. TAF/FTC/BIC accounted for 53.6% of initial prescriptions in 2020, followed by DTG/3TC (24%). The percentage of patients on ART increased from 45.7% in 2004 to 98.2% in 2020. Among all patients receiving ART, regimens based on 2NRTI plus 1INI increased from 0.1% in 2007 to 53.3% in 2020. During 2007–2015, most patients were receiving TDF/FTC/EFV, which was replaced after 2017 by ABC/3TC/DTG. In 2020, 13.0% of patients were receiving dual therapies. Conclusions: Robust real-world data on ART use in PLWHIV over more than 15 years show historical trends in prescriptions with an unprecedented visualization of the contemporary treatment patterns. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

10. Vigilancia epidemiológica de la infección por el VIH: situación en la Unión Europea y en España, 2018

Author

Hernando, Victoria, Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Ruiz-Algueró, Marta, Díaz, Asunción, vigilancia del VIH/sida, Responsables autonómicos de, and Los responsables de los registros autonómicos de VIH/sida

Subjects
Infección por el VIH, sida, vigilancia epidemiológica
Abstract

[ES] A continuación se presentan los principales resultados de la vigilancia de la infección por el virus de la inmunodeficiencia humana (VIH) en los países de la Unión Europa/Área Económica Europa (UE/AEE) y España correspondientes al año 2018, así como las tendencias en España en el periodo 2009-2018. La tasa de nuevos diagnósticos de VIH en España en 2018 fue superior a la media de la UE/AEE (8,6/100.000 habitantes en España y 5,8 en la UE/AEE, corregidas por retraso en la notificación), aunque es similar a la de otros países del entorno. La vía de transmisión más importante sigue siendo la sexual, ocupando el primer lugar las relaciones sexuales no protegidas entre hombres. Los datos muestran, tanto en España como en la UE/AEE, que casi la mitad de los nuevos diagnósticos en 2018 fueron tardíos y la tendencia se mantiene estable en los últimos años. El grupo de edad más afectado son los adultos entre 25 y 39 años. La tendencia de las tasas entre 2009 y 2018 es ligeramente descendente, variando según la categoría de transmisión. Entre personas que se inyectan drogas y los casos heterosexuales es decreciente. Por grupos de edad, la tendencia es descendente en todos ellos, excepto entre 25 y 29 años que se mantiene estable. [EN] This report shows the main results about HIV surveillance in European Union/European Economic Area (EU/EEA) and Spain in 2018, and the trends in Spain in the period 2009-2018. The rate of new HIV diagnoses in Spain was higher than the average in UE/EEA (8.6/100.000 population in Spain and 5.8 in EU/EEA, adjusting for report delay), although is similar to other neighbor countries. Sexual transmission is still the most important route of transmission, and the unprotected sexual relationships between men were the highest proportion of cases. In Spain, as well as EU/EEA countries, nearly half of new HIV diagnosed in 2018 were late presenters and the trend remains stable. Adults aged between 25 and 39 years were the largest age group. The rate trend is slightly decreased during the period 2009-2018, changing by category of transmission. Among persons who injecting drugs and heterosexuals, the trend is descending. By age group, the trend is descending, except between 25 and 29 that remains stable.

Published
2020

11. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

Author

Instituto de Salud Carlos III, European Commission, Suárez-García, Inés, Moreno, Cristina, Ruiz-Algueró, Marta, Pérez-Elías, María Jesús, Navarro, Marta, Díez Martínez, Marcos, Viciana, Pompeyo, Pérez-Martínez, Laura, Górgolas-Hernández-Mora, Miguel, Amador, Concha, Zárraga, Miguel Alberto de, Jarrín, Inma, Instituto de Salud Carlos III, European Commission, Suárez-García, Inés, Moreno, Cristina, Ruiz-Algueró, Marta, Pérez-Elías, María Jesús, Navarro, Marta, Díez Martínez, Marcos, Viciana, Pompeyo, Pérez-Martínez, Laura, Górgolas-Hernández-Mora, Miguel, Amador, Concha, Zárraga, Miguel Alberto de, and Jarrín, Inma

Abstract

[Background]: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS)., [Methods]: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml at the start of the regimen)., [Results]: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure., [Conclusions]: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.

Published
2020

12. Use of health resources and costs associated to first-line antiretroviral therapy in the era of integrase inhibitors

Author

Ruiz Algueró, Marta, Suárez García, Inés, Álvarez del Arco, Débora, Lázaro, Pablo, Moreno, S., and Jarrín, Inmaculada

Subjects
Servicio de salud, Antirretrovirales, Sida, Investigación médica, Técnica Delfos, health care economics and organizations
Abstract

Introduction: We aimed to evaluate the usage of health resources and the associated costs during the first year of treatment with the most commonly used first-line antiretroviral regimens (ART) in the Cohort of the Spanish AIDS Research Network in the era of integrase inhibitors. Methods: We used a cost evaluation model in which the use of health resources derived from initiating a regimen was estimated using a two-round Delphi method with a structured questionnaire in a pannel of 35 HIV experts. The cost of initiating a regimen included the costs of ART, clinical management and management of adverse effects (AE). The payer perspective (National Health System) was applied. Thus, only direct costs were considered. Results: In an intention-to-treat analysis, the annual cost ranged from 8,501 (sic) for TDF/FTC/EFV to 12,840 (sic) for TDF / FTC + RAL. On average, the pharmacological cost accounts for 87.6% varying between 83.8% for TDF/FTC/EFV and 91.1% for TDF/FTC+RAL. The cost of clinical management accounts for 11.5% of the total cost, ranging from 8.6% for TDF/FTC+RAL and 13.9% for ABC / 3TC / DTG. Only 0.9% of the total cost is due to management of AE, higher with the use of TDF/FTC/EFV (2.6%) and TDF/FTC+DRV / r (1.1%). Conclusion: The cost for the health system of the first year of antiretroviral treatment is mainly driven by the price of drugs. The regimens with lowest total cost were TDF/FTC/EFV, TDF/FTC/RPV and ABC/3TC/DTG, and the ones with highest total cost were TDF/FTC/EVG/COBI and TDF/FTC+RAL. Sin financiación No data JCR 2019 0.108 SJR (2019) Q4, 38/44 Pharmacy No data IDR 2019 UEM

Published
2019

14. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single‐tablet regimen in a multicentre cohort in Spain.

Author

Suárez‐García, Inés, Alejos, Belén, Ruiz‐Algueró, Marta, García Yubero, Cristina, Moreno, Cristina, Bernal, Enrique, Pérez‐Is, Laura, Zubero, Zuriñe, Zárraga Fernández, Miguel Alberto, Samperiz Abad, Gloria, and Jarrín, Inma

Subjects
DOLUTEGRAVIR, ABACAVIR, LAMIVUDINE, PILLS, VIRAL load, HIV infections
Abstract

Introduction: We aimed to assess the effectiveness and tolerability of dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) administered as branded STR (DTG/ABC/3TC) or as two separate pills (DTG and either branded ABC/3TC [DTG+(ABC/3TC)b] or generic ABC/3TC [DTG+(ABC/3TC)g]). Methods: We included individuals from the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) who received DTG/ABC/3TC, DTG+(ABC/3TC)b or DTG+(ABC/3TC)g during 2015 to 2018. We used multivariable logistic regression to compare the proportion of antiretroviral‐naïve individuals who achieved viral suppression (VS) (viral load ≤50 copies/mL) at 24 weeks of initiating with DTG+(ABC/3TC)b or DTG+(ABC/3TC)g versus DTG/ABC/3TC. We also calculated the proportion of virologically suppressed individuals who maintained VS at 24 weeks after switching from DTG/ABC/3TC to DTG+(ABC/3TC)g. Results: During the study period, 829, 68 and 47 treatment‐naïve individuals started treatment with DTG/ABC/3TC, DTG+(ABC/3TC)b or DTG+(ABC/3TC)g respectively. The proportions of individuals who changed their regimens due to side effects during the first 24 weeks were 3.7%, 4.4% and 6.4% respectively (p = 0.646). We did not find significant differences in VS at 24 weeks among individuals starting with DTG+(ABC/3TC)b or DTG+(ABC/3TC)g compared to those initiating with DTG/ABC/3TC. Among 177 virologically suppressed individuals who switched from DTG/ABC/3TC to DTG+(ABC/3TC)g, 170 (96.0%) maintained VS at 24 weeks. Conclusions: In naïve individuals, the effectiveness and tolerability at 24 weeks of DTG plus ABC/3TC administered as two separate pills, either as branded or generic ABC/3TC, was similar to the STR DTG/ABC/3TC. Switching the STR DTG/ABC/3TC to its separate components DTG+(ABC/3TC)g in virologically suppressed individuals did not seem to impair its effectiveness. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study.

Author

Ruiz-Algueró, Marta, Hernando, Victoria, Marcos, Henar, Gutiérrez, Gonzalo, Pérez-Elías, Maria Jesus, López-Bernaldo de Quirós, Juan Carlos, Pulido, Federico, Górgolas, Miguel, Sanz, Jesus, Suarez-García, Ines, Fernandez, Maria Teresa, Losa, Juan Emilio, Pérez, Jose Luis, Ladrero, Maria Oliva, Prieto, Miguel Ángel, González, Gustavo, Izquierdo, Ana, Viloria, Luis Javier, López, Irene, and Martínez, Eva

Subjects
*HIV infections, *HIV, *QUALITY of life, *VIRAL load, *CROSS-sectional method
Abstract

Background: HIV infection has become a chronic disease and well-being of people living with HIV (PLHIV) is now of particular concern. The objectives of this paper were to describe self-rated health among PLHIV, on ART and on ART virally suppressed and to analyse its determinants.Methods: Data were obtained from a second-generation surveillance system based on a cross-sectional one-day survey in public hospitals. Epidemiological and clinical data were collected among HIV-infected inpatients and outpatients receiving HIV-related care the day of the survey in 86 hospitals in 2019. Self-rated health was measured using a question included in the National Health Survey: "In the last 12 months, how would you rate your health status?" an ordinal variable with five categories (very good, good, moderate, bad and very bad). For the analysis, these responses were dichotomized into two categories: 1 = very good/good and 0 = moderate, bad or very bad health status. Factors associated with very good/good self-rated health were estimated using logistic regression.Results: Of 800 PLHIV, 67.5% perceived their health as very good/good, 68.4% among PLHIV on ART and 71.7% of those virally suppressed. Having university education (adjusted odds ratio (aOR):2.1), being unemployed (aOR:0.3) or retired (aOR:0.2), ever being diagnosed of AIDS (aOR:0.6), comorbidities (aOR:0.3), less than 2 year since HIV diagnosis (aOR:0.3) and not receiving ART (aOR:0.3) were associated with good self-rated health. Moreover, among PLHIV on ART, viral load less than 200 copies (aOR:3.2) were related to better perceived health. Bad adherence was inversely associated with good self-rated health among PLHIV on ART (aOR:0.5) and of those virally suppressed (aOR:0.4).Conclusions: Nearly seven in 10 PLHIV in Spain considered their health status as very good/good, being higher among virally suppressed PLHIV. Both demographic and clinical determinants affect quality of life. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.

Author

Suárez-García, Inés, Moreno, Cristina, Ruiz-Algueró, Marta, Pérez-Elías, María Jesús, Navarro, Marta, Díez Martínez, Marcos, Viciana, Pompeyo, Pérez-Martínez, Laura, Górgolas, Miguel, Amador, Concha, de Zárraga, Miguel Alberto, Jarrín, Inma, the Cohort of the Spanish HIV/AIDS Research Network (CoRIS), Moreno, Santiago, Dalmau, David, Navarro, Maria Luisa, González, Maria Isabel, Garcia, Federico, Poveda, Eva, and Iribarren, Jose Antonio

Subjects
COMBINATION drug therapy, DRUG tolerance, HIV infections, LONGITUDINAL method, MEDICAL cooperation, MEDICAL practice, RESEARCH, VIRAL load, TREATMENT effectiveness, DARUNAVIR, EMTRICITABINE-tenofovir
Abstract

Background: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Methods: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml at the start of the regimen). Results: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure. Conclusions: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. [Impacto de la pandemia de la COVID-19 en los sistemas de vigilancia epidemiologica de la infección por vih en España.]

Author

Hernando Sebastián V, Ruiz-Algueró M, Simón Méndez L, and Díaz Franco A

Subjects
Humans, Pandemics, Communicable Disease Control, Spain epidemiology, Retrospective Studies, COVID-19 diagnosis, COVID-19 epidemiology, HIV Infections diagnosis, HIV Infections epidemiology
Abstract

Objective: The COVID-19 pandemic indirectly affected other communicable diseases, such as human immunodeficiency virus (HIV) infection. The aim of this paper was to evaluate the impact of the COVID-19 pandemic on the epidemiological surveillance of HIV through epidemiological indicators., Methods: Data collected in the New HIV Diagnosis Information System (SINIVIH, acronym in Spanish) in the period 2013-2021 was analyzed. The epidemiological indicators analyzed were: 1) Reporting delay of new diagnoses; 2) Under diagnosis of cases, calculated per month of diagnosis and for each year of diagnosis; 3) Late diagnosis, cases diagnosed with less than 350 CD4 cell/mm 3 ., Results: Regarding the reporting delay of new diagnoses, in 2022 2,770 diagnoses were reported in 2020, 43.8% more than those reported in 2021 for that year. The cases diagnosed per month between 2016 and 2019 followed a constant trend. In 2020, a significant decrease in diagnoses was observed between March and May that was not recovered after correcting for reporting delay. When comparing the rates of cases diagnosed in 2013 with the successive years, a continuous decrease was interrupted in the last year of the study period. The percentage of cases with late diagnosis had remained stable in the study period (between 46% and 50%), and a decrease in this percentage was observed after correcting for reporting delay., Conclusions: The epidemiological surveillance of HIV suffered a significant reporting delay. A decrease in cases diagnosed is confirmed, partly due to lockdown and lack of access to the health system. Changes on late diagnosis is not observed.

Published
2023

18. Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort.

Author

Suárez-García I, Ruiz-Algueró M, Alejos B, García-Yubero C, Belza MJ, Espacio R, Hernández J, Muñoz Sánchez J, Garaialde A, Alonso Socas MDM, Alcaraz A, Pierola Ruiz de Galarreta B, Martínez Madrid OJ, Gutiérrez Cuéllar I, Gómez-Ayerbe C, Olalla J, and Jarrín I

Subjects
Drug Combinations, Emtricitabine therapeutic use, Humans, Lamivudine therapeutic use, Quality of Life, Surveys and Questionnaires, Tablets, Tenofovir therapeutic use, Anti-HIV Agents therapeutic use, HIV Infections drug therapy
Abstract

Objectives: The aims of this study were to describe patients' experiences after single-tablet regimen (STR) desimplification and its impact on self-reported treatment adherence and quality of life., Methods: We performed a survey among all patients from the multicenter cohort of the Spanish HIV/AIDS Network who had desimplified the STRs dolutegravir/abacavir/lamivudine (DGT/ABC/3TC) or rilpivirine/tenofovir disoproxil fumarate/emtricitabine to their separate components (DTG + generic ABC/3TC or RPV + generic TDF/FTC) between December 2016 and November 2018., Results: Among 216 patients who fulfilled inclusion criteria, 138 (63.9%) completed the questionnaire. Most of the patients (78.3%) knew what generic drugs are, only 8.7% believed that treatment with 2 pills is less effective than treatment with an STR, and 67.4% agreed that it is reasonable to take 2 pills instead of 1 for HIV treatment to decrease costs for the health care system. After desimplification, 13.0% of the patients stated they had more secondary effects, 8.0% had forgotten one or more doses more frequently than before, and 10.9% had sometimes forgotten to take 1 pill, but not the other. A proportion of 30.4% reported not being happy to take more pills a day, and 10.1% experienced a worse quality of life after the treatment desimplification., Conclusions: After STR desimplification, most of the patients had a fair knowledge about generic antiretrovirals, and they agreed to desimplify their STR to decrease costs. Although almost a third of the respondents were not happy to take 2 pills a day, only a minority reported worse adherence or quality of life., Competing Interests: I.S.G. has received conference or speaker fees from ViiV, MSD, and Gilead. C.G.Y. has received conference fees from Gilead and Janssen. I.J. has received teaching fees from ViiV and advisory fees from Gilead. The remaining authors have no conflicts of interest to disclose., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results